Breaking News
March 20, 2019 - Leaky valve repair improves quality of life in heart failure patients
March 20, 2019 - Diattenuation Imaging offers structural information of difficult to access brain regions
March 20, 2019 - Early sports specialization linked to increased injury rates during athletic career
March 20, 2019 - Study brings clarity about milk intake for children with Duarte galactosemia
March 20, 2019 - Allergan Announces FDA Acceptance of New Drug Application for Ubrogepant for the Acute Treatment of Migraine
March 20, 2019 - Maternal smoking during pregnancy increases risk of ADHD among offspring up to three-fold
March 20, 2019 - Pioneering pediatric kidney transplant surgeon Oscar Salvatierra dies at 83 | News Center
March 20, 2019 - F.D.A. Approves First Drug for Postpartum Depression
March 20, 2019 - TB remains a major public health challenge in the European region
March 20, 2019 - Most pills contain common allergens, warn experts
March 20, 2019 - Researchers discover previously unknown mechanism by which cells can sense oxygen
March 20, 2019 - World’s leading source of data on diagnosis, treatments for aortic dissection
March 20, 2019 - Breast cancer relapse predictor may soon be a reality
March 20, 2019 - Researchers identify origin of chronic pain in humans
March 20, 2019 - Two-drug combinations containing calcium channel blocker significantly lowers BP
March 20, 2019 - King’s scientists to monitor air quality exposure of 250 children
March 20, 2019 - Preventative cardioverter defibrillator implantation is of little benefit to kidney dialysis patients
March 20, 2019 - Merck to collaborate with GenScript for plasmid and virus manufacturing in China
March 20, 2019 - FDA Approves Zulresso (brexanolone) for the Treatment of Postpartum Depression
March 20, 2019 - Study examines long-term opioid use in patients with severe osteoarthritis
March 20, 2019 - Retired Stanford professor Edward Rubenstein, pioneer in intensive care medicine, dies at 94 | News Center
March 20, 2019 - Aaron Diamond AIDS Research Center to Join Columbia University
March 20, 2019 - Call for halt to human gene editing and designer babies experiments
March 20, 2019 - Study illuminates how hot spots of genetic variation evolved in the human genome
March 20, 2019 - Roundworm study suggests alternatives for treatment of schizophrenia
March 20, 2019 - Sphingotec reports new applications of bio-ADM at 39th ISICEM
March 20, 2019 - Preventing falls through free community-based screenings for older adults
March 20, 2019 - AAOS: Supplement Use Low in Patients With Osteoporosis, Hip Fracture
March 20, 2019 - Does intensive blood pressure control reduce dementia?
March 20, 2019 - Nut consumption could be key to better cognitive health in older people
March 20, 2019 - Drinking hot tea associated with increased risk of esophageal cancer
March 20, 2019 - Androgen receptor plays vital role in regulating multiple mitochondrial processes
March 20, 2019 - NIH announces funding boost for Detroit Cardiovascular Training Program
March 20, 2019 - Study reveals another surgical option for patients with irreparable rotator cuff tears
March 20, 2019 - New robot-guided video game may be effective and low-cost solution for caregivers
March 20, 2019 - Heart Attacks Fall By One-Third Among Older Americans
March 20, 2019 - Data sharing uncovers five new risk genes for Alzheimer’s disease
March 20, 2019 - Does It Make Sense To Delay Children’s Vaccines?
March 20, 2019 - Lack of health insurance may increase Aging immigrants’ risk for cardiovascular disease
March 20, 2019 - Piece of puzzle unlocked in what drives alcohol addiction
March 20, 2019 - Researchers investigate whether Zika reservoirs are found in the Americas
March 20, 2019 - Compounds found in coffee may inhibit growth of prostate cancer
March 20, 2019 - Lab Innovations returns to the NEC on 30 & 31 October 2019
March 20, 2019 - How genes affect tobacco and alcohol use
March 20, 2019 - Osteoarthritis and rheumatoid arthritis have similar impacts on patients
March 20, 2019 - Individuals with infection history have higher risk of developing Sjögren’s syndrome
March 20, 2019 - Nursing home residents benefit from individualized multi-component exercise program
March 20, 2019 - Plant cellulose bone implants are “viable” option to support new bone growth, study finds
March 20, 2019 - Older people living in retirement communities benefit from improved health
March 20, 2019 - UTSA professor helps train first responders to detect prescription opioid overdoses
March 20, 2019 - Biohaven’s Verdiperstat Receives Orphan Drug Designation From FDA For Multiple System Atrophy
March 20, 2019 - Smoking may limit body’s ability to fight dangerous form of skin cancer
March 20, 2019 - Researchers receive $9.7-million grant to develop new hearing-loss treatments for deaf
March 20, 2019 - TGen and ABL sign agreement to distribute new TB test technology
March 20, 2019 - UCD researchers lead development of new urine test to detect prostate cancer
March 20, 2019 - Miniature brains that can move muscles, grown in the lab
March 20, 2019 - Servier and Oncodesign announce research and drug development partnership
March 20, 2019 - FDA warns marketer of unapproved products claiming to treat addiction, chronic pain
March 20, 2019 - TB Medicine Pretomanid Enters Regulatory Review Process in the United States
March 20, 2019 - Breastfeeding can erase effects of prenatal violence for newborns
March 20, 2019 - Tens of Thousands of Heart Patients May Not Need Open-Heart Surgery
March 20, 2019 - Space worries – shingles affecting astronauts says NASA
March 20, 2019 - Study shows how AI can improve physicians’ diagnostic accuracy
March 20, 2019 - Dolomite Bio launches new scRNA-Seq Reagent Kit at AGBT 2019
March 20, 2019 - World’s oldest semen viable for artificial insemination
March 20, 2019 - FDA Approves Zulresso (brexanolone) for the Treatment of Post-Partum Depression
March 19, 2019 - How it manipulates us to tribalism
March 19, 2019 - How can doctors encourage patients to adopt healthier behaviors?
March 19, 2019 - Meet Hal: He's One Sick Robot
March 19, 2019 - Blood test and mathematical model can estimate preterm birth rate in low-resource countries
March 19, 2019 - TAVR procedure safe in patients with unusual valve anatomy
March 19, 2019 - Proteins in the eye may be potential source for cost-effective test to predict Alzheimer’s disease
March 19, 2019 - Opioid Prescriptions Dropped for New Users From 2012 to 2017
March 19, 2019 - New method may better predict the best treatment for burn wounds
March 19, 2019 - “Asian” isn’t specific enough for health data, research suggests
March 19, 2019 - ColumbiaDoctors Presents Honors for Outstanding Commitment to Patient Safety
March 19, 2019 - Innovative model identifies primate species with potential to transmit Zika in the Americas
March 19, 2019 - One-off surgery could offer hope to patients with high blood pressure
March 19, 2019 - Many pet owners interested in feeding their pets with plant-based diet
March 19, 2019 - How to Protect Your Kids From Drowning
Study opens new potential avenue for treating ovarian cancer

Study opens new potential avenue for treating ovarian cancer

image_pdfDownload PDFimage_print

Researchers at Houston Methodist Research Institute and The University of Texas MD Anderson Cancer Center have found a prescription drug, Calcitriol, approved by the Food and Drug Administration for the treatment of calcium deficiency and kidney diseases, may increase the likelihood of surviving ovarian cancer.

Their preclinical research, reported in the Journal of the National Cancer Institute, integrated computational modeling and biology experiments in cell lines and mouse models to pinpoint a molecular pathway between malignant cells and supportive cells, called fibroblasts, associated with poor prognosis for patients with high-grade serous ovarian cancer, the most common and difficult form of the disease.

A review of potential drugs by Houston Methodist researchers indicated that a synthetic and active form of a vitamin D analog called Calcitriol might break up molecular communication between cancer cells and fibroblasts, a finding confirmed in mouse models by MD Anderson researchers.

This study opens a new potential avenue for treating ovarian cancer. Since Calcitriol is an FDA-approved drug, no additional research is needed before the drug can advance to human clinical trials for ovarian cancer. The researchers are working to address regulatory procedures, planning and funding required to open a clinical trial.

“Targeting cancer cells might not be the only solution to treating cancer. Other cells in the tumor and surrounding microenvironment, such as fibroblasts, immune cells, fat cells and other supportive cells make up the very complex ecosystem of tumors that we need to understand,” said Samuel Mok, Ph.D., professor of Gynecologic Oncology and Reproductive Medicine and co-senior author of the study.

Using a computer modeling technique pioneered by co-senior author Stephen Wong, Ph.D., the Houston Methodist team processed and analyzed genomic big data to identify crosstalk targets and screen FDA-approved drugs. Their approach allowed them to look at the complexity of the interactions among tumor cells and different types of supporting cells to see a full map of their intricacies.

“In this era of big data, we can systematically identify pathways and therapies, as we’re using an unbiased approach to look at all possibilities,” said Wong, chair of systems medicine and bioengineering and John S. Dunn Sr. Presidential Distinguished Chair in Biomedical Engineering at Houston Methodist. “Our computational modeling can tell you which pathway is important for a particular disease. It allows for the heterogeneous tumor data to be fed in to the model to precisely identify these pathways, giving us a comprehensive view and allowing us to see specifically which malfunctioning cells to target.”

Fibroblasts make and maintain connective tissue that provides a scaffolding for organs. To better understand their role, Mok, co-lead author Tsz-Lun Yeung, Ph.D., and colleagues carved out fibroblasts from tumor samples to study separately, using a precise process called laser microdissection.

They studied gene expression by these cancer-associated fibroblasts (CAFs) and found the fibroblasts had two distinct expression, or signatures that they named CAF-C and CAF-N.

“A survival analysis of these two CAF types in 46 ovarian cancer patients showed that patients with CAF-C fibroblasts had a poor prognosis, with median overall survival of 16 months compared to 33 months for the other type,” Mok said.

Smad signaling between cancer cell, fibroblasts

The next step was to sort out what, specifically, makes the CAF-C group promote aggressive disease. Using a multi-cellular crosstalk modeling tool developed by Wong, called CCCExplorer (Cell-Cell Communication Explorer), co-lead author Jianting Sheng, Ph.D., and colleagues of the Houston Methodist team input gene-expression profiles from micro-dissected fibroblasts and neighboring ovarian cancer cells provided by Mok to compute, predict and prioritize crosstalk pathways and cell-to-cell interactions in the tumor microenvironment.

“We identified a signaling pathway, called Smad, as the culprit of poor ovarian cancer outcomes,” Wong said. “Reprogramming these cells by targeting their communication networks presents an opportunity for the development of new cancer treatment strategies. If we focus on targeting these supportive cells in the tumor microenvironment instead of the tumor, itself, it could lead to less toxic, more effective treatments.”

Experiments by Mok and colleagues confirmed the primacy of Smad signaling. Gene expression analysis again clustered patients into two groups; those with high expression of Smad-regulated genes had median overall survival of 15 months compared to 26 months for those with low expression.

Wong and colleagues at Houston Methodist applied another computational module in their CCCExplorer tool to predict known drugs that have passed phase I safety trials that might target Smad signaling. Calcitriol was selected for further studies in part because previous research shows it can inhibit the binding of Smad proteins to their target genes.

MD Anderson cell line experiments showed Calcitriol blocks Smad signaling. Treating ovarian-tumor bearing mice with Calcitriol reduced cancer cell proliferation and tumor volume while lengthening median overall survival from 36 to 48 weeks.

“We know that cells in the tumor microenvironment actually support the cancer and may contribute to its aggressiveness. This study opens up a new potential avenue for developing ovarian cancer treatments,” said co-author Karen Lu, M.D., chair of Gynecologic Oncology and Reproductive Medicine at MD Anderson and J. Taylor Wharton, M.D., Distinguished Chair in Gynecologic Oncology.

“These researchers have developed a unique and powerful concept to decode crosstalk and interactions among different cell components in the complex tumor microenvironment,” said Jenny C. Chang, M.D., director of Houston Methodist Cancer Center and Emily Herrmann Chair in Cancer Research. “Instead of testing one hypothesis at a time, the modeling tool now allows the cancer researchers and drug designers to comprehensively evaluate major intercellular crosstalk pathways simultaneously to find novel targets for ovarian and other cancers.”

Source:

https://www.mdanderson.org/newsroom/2018/06/md-anderson-houston-methodist-scientists-detect-new-ovarian-cancer-target.html

Tagged with:

About author

Related Articles